SCHEMBL6541667

SCHEMBL6541667

COc1cc(C)c(S(=O)(=O)Nc2ccc(Cl)c(OCCN(C)C)c2)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 5/20 0.58
THRB P10828 2/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B2 P37059 1/20 0.44
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CDK7 P50613 1/20 0.43
CCNH P51946 1/20 0.43
CCNA1 P78396 1/20 0.43
HPGD P15428 1/20 0.43
LMNA P02545 4/20 0.42
HTT P42858 2/20 0.42
SGK1 O00141 1/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 1/20 0.41
ALPL P05186 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542576 0.91 UTS2R (0.60) UTS2RTHRBSMN1; SMN2MEN1KMT2A
SCHEMBL6542101 0.89 HSD17B1 (0.50) UTS2RTHRBSMN1; SMN2MEN1KMT2A
SCHEMBL6177410 0.88 UTS2R (0.74) UTS2RSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL6175070 0.86 UTS2R (0.46) UTS2RTHRBHSD17B2LMNAHTT
SCHEMBL6541535 0.85 UTS2R (0.67) UTS2RTHRBSMN1; SMN2MEN1KMT2A
SCHEMBL6541415 0.85 UTS2R (0.48) UTS2RSMN1; SMN2MEN1KMT2AHSD17B2
SCHEMBL6542874 0.84 LMNA (0.51) UTS2RSMN1; SMN2MEN1KMT2ACDK1
SCHEMBL6542847 0.84 SMN1; SMN2 (0.57) UTS2RSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL6542791 0.84 LMNA (0.63) UTS2RTHRBSMN1; SMN2MEN1KMT2A
SCHEMBL6542559 0.81 PPARG (0.48) UTS2RMEN1KMT2ACDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP claimed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US claimed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP claimed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO claimed
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP disclosed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP disclosed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR UTS2R 1/4885THRB 1275/4885SMN1; SMN2 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.